Conventional nuclear medical imaging uses radiopharmaceuticals labeled by single-photon emitters such as Tc-99m, I-123, or I-131 in vivo. Classical clinical examples are the study of bone metabolism by bone scintigraphy with the Tc-99m-labeled polyphosphonates or of iodine transport into the thyroid gland using Tc-99m-pertechnetate. With single-photon emission-computed tomography (SPECT), the distribution of these radiopharmaceuticals within the human body is three-dimensionally visualized. Contrary to positron emission tomography (PET), current SPECT technology does not allow the quantification of regional values of radioactivity tissue concentration as SPECT images are grossly compromised by artifacts caused by photon scatter and attenuation. With the advent of hybrid imaging systems combining a SPECT camera with an X-ray computerized (CT) scanner in one gantry, reliable corrections for these artifacts seem possible, allowing truly quantitative SPECT.